Orange Book product · Generic (ANDA)
IMIQUIMOD
IMIQUIMOD
At a glance
Jan 26, 2021
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jan 26, 2021
5 yr 6 mo ago
Today
Pharmaceutical detail
Active ingredient
IMIQUIMOD
Strength
3.75%
Dosage form
CREAM
Route
TOPICAL
TE code
AB
Application
ANDA 205971
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of IMIQUIMOD
- 2011ZYCLARABrand (NDA)
NDA 022483 · BAUSCH
- 1997ALDARABrand (NDA)
NDA 020723 · BAUSCH
- 2014IMIQUIMODGeneric (ANDA)
ANDA 202002 · STRIDES PHARMA
- 2012IMIQUIMODGeneric (ANDA)
ANDA 091308 · APOTEX INC
- 2012IMIQUIMODGeneric (ANDA)
ANDA 201994 · GLENMARK PHARMS
- 2011IMIQUIMODGeneric (ANDA)
ANDA 200481 · COSETTE
- 2011IMIQUIMODGeneric (ANDA)
ANDA 200173 · TARO
- 2011IMIQUIMODGeneric (ANDA)
ANDA 091044 · ENCUBE
- 2010IMIQUIMODGeneric (ANDA)
ANDA 078837 · PADAGIS ISRAEL
- 2010IMIQUIMODGeneric (ANDA)
ANDA 078548 · FOUGERA PHARMS
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
